Barclays Maintains an 'Equalweight' on Hologic (HOLX); Tomo-focus at RSNA Analyst Event
Tweet
Share
E-mailGet Alerts HOLX Hot Sheet
Price: $76.71 -0.62%
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 3 | New: 2
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 3 | New: 2
Join SI Premium – FREE
Barclays maintains an 'Equalweight' on Hologic (NASDAQ: HOLX) price target of $17.00.
Barclays analyst says, "The highlights were customer presentations on clinical usage and positive early experience with tomo, and preliminary tomo data from ongoing clinical trials. No change to financial guidance or our estimates, but we are encouraged by the degree of customer interest and initial traction seen by the company (>100 systems placed)."
"HOLX reiterates CPT code on track for 2013: HOLX highlighted four promising but preliminary tomo studies presented at RSNA...'TMIST' on the horizon: The 3D mammography market is set to see competitive entries over the next couple of years, and plans are afoot for an ACR-conducted
multi-vendor, prospective trial ('TMIST') similar to the 2005 DMIST study for FFDM."
"Two upcoming tomo-related FDA submissions: 1) PMA supplement for C-View (reconstructs 2D images from 3D data), with launch expected in 2013. The calcification enhancement capability will follow ~6 months after that; 2) 510(k) submission for Affirm for tomo-guided biopsies by YE12."
For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.
Shares of Hologic closed at $16.55 yesterday.
Barclays analyst says, "The highlights were customer presentations on clinical usage and positive early experience with tomo, and preliminary tomo data from ongoing clinical trials. No change to financial guidance or our estimates, but we are encouraged by the degree of customer interest and initial traction seen by the company (>100 systems placed)."
"HOLX reiterates CPT code on track for 2013: HOLX highlighted four promising but preliminary tomo studies presented at RSNA...'TMIST' on the horizon: The 3D mammography market is set to see competitive entries over the next couple of years, and plans are afoot for an ACR-conducted
multi-vendor, prospective trial ('TMIST') similar to the 2005 DMIST study for FFDM."
"Two upcoming tomo-related FDA submissions: 1) PMA supplement for C-View (reconstructs 2D images from 3D data), with launch expected in 2013. The calcification enhancement capability will follow ~6 months after that; 2) 510(k) submission for Affirm for tomo-guided biopsies by YE12."
For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.
Shares of Hologic closed at $16.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Berenberg Starts Lloyds TSB Group (LYG) at Hold, 'shares are fairly valued'
- Ascendis Pharma (ASND) Announces UK Approval of YORVIPATH
- enVVeno Medical (NVNO) Reports Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from VenoValve
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
